List of Thalomid drug patents

Thalomid is owned by Celgene.

Thalomid contains Thalidomide.

Thalomid has a total of 1 drug patent out of which 0 drug patents have expired.

Thalomid was authorised for market use on 16 July, 1998.

Thalomid is available in capsule;oral dosage forms.

The generics of Thalomid are possible to be released after 09 December, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7230012 CELGENE Pharmaceutical compositions and dosage forms of thalidomide
Dec, 2023

(8 months from now)

Drugs and Companies using THALIDOMIDE ingredient

Market Authorisation Date: 16 July, 1998

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of THALOMID before it's patent expiration?
More Information on Dosage

THALOMID family patents

5

United States

2

China

2

Taiwan, Province of China

2

Japan

2

Australia

2

European Union

1

Portugal

1

Spain

1

Brazil

1

New Zealand

1

Mexico

1

Korea, Republic of

1

Hong Kong

1

South Africa

1

Canada

1

Cyprus

1

Slovenia

1

Israel

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic